Janssen seeks EMA approval for novel subcutaneous formulation of DARZALEX® (daratumumab)
Janssen announced submission of an extension application to the EMA for subcutaneous use of DARZALEX® (daratumumab) for treatment of patients with multiple myeloma. This subcutaneous formulation of daratumumab is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20). July 22, 2019